[Therapeutic antiradiation properties of leukinferon].
In experiments with three species of animals (mice, rabbits, monkeys) irradiated with sublethal and lethal doses of gamma-irradiation, it was observed, that leukinferon used in 4 hours or 10 days after provided antiradiation therapeutical effect. When lethal dose was used (mice) the survival of animals was significantly increased. The preparation decreased depression of the functional activity of leukocytes as it was observed with IFH-alpha and gamma-production. Pestoring this function was accelerated. Phenomena pancytopenia and thrombocytopenia induced by radiation were decreased. Therapeutical effect was explained with capacity of the preparation to defence the hemopoietic organs from the radiation and to stimulate hematopoiesis. So, spleen weights and quantity of cells into bone marrow were higher in experimental group in comparison with control at any observation. CFUs were also higher (with optimal dose of preparation). Stimulation of the restoring processes was confirmed also by more intensive increasing of the reticulocyte quantities in the circulation of experimental monkeys within 20 days. Then their level became more close in both groups. The preparation stimulated also differentiation of immune effectors: immature neutrophils were absent in the circulation of experimental monkeys. Production of IFN-gamma (which is function of T-lymphocytes) was restored more fast. As a result, immunoreactivity of monkeys in experimental group was more complete and restored faster: the growth of the automicroflora on the skin surface became to increase 7 days later and was restrained. Leukinferon hindered the development of acute radiation sickness symptoms.
Ivanov
A A
AA
State Scientific Centre of Russuan Federation, Institute of Biophysics, Moscow.
Kuznetsov
V P
VP
Ulanova
A M
AM
Stavrakova
N M
NM
Kuz'mina
T D
TD
Leonenko
I V
IV
Gutsenko
K K
KK
Shal'nova
G A
GA
Beliaev
D L
DL
Babaiants
A A
AA
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D000882:Haplorhini; D006410:Hematopoiesis / Q000187:drug effects / Q000528:radiation effects; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D051379:Mice; D011817:Rabbits; D011829:Radiation Dosage; D011833:Radiation Injuries, Experimental / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D011837:Radiation-Protective Agents; D012867:Skin / Q000382:microbiology; D013154:Spleen / Q000187:drug effects / Q000528:radiation effects; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; D016898:Interferon-alpha; D011837:Radiation-Protective Agents; C062252:leukinferon; D007371:Interferon-gamma
Protivoluchevye terapevticheskie svoĭstva leĭkinferona,